首页|非小细胞肺癌多发脑转移患者应用厄洛替尼联合全脑放射临床治疗观察及对血管内皮生长因子C水平的影响

非小细胞肺癌多发脑转移患者应用厄洛替尼联合全脑放射临床治疗观察及对血管内皮生长因子C水平的影响

扫码查看
目的 研究分析非小细胞肺癌多发脑转移患者应用厄洛替尼联合全脑放射临床治疗观察及对血管内皮生长因子C水平的影响.方法 选取本院2015年1月~2016年4月收治的40例非小细胞肺癌多发脑转移患者为研究对象,随机分为对照组和实验组,每组患者各为20例.对照组和实验组患者均进行全脑放射临床治疗,对照组给予常规治疗,实验组给予厄洛替尼.比较分析2组患者的临床治疗效果.结果 经过对应的治疗后,实验组20例患者中,8例患者完全缓解,7例患者部分缓解,治疗有效例数为15例,治疗有效率为75.0%.对照组患者中,6例患者完全缓解,4例患者部分缓解,治疗有效率为50.0%.可得,实验组患者治疗有效率(75.0%)显著高于对照组(50.0%),具有统计学意义(P<0.05).实验组患者1年后生存率(80.0%)显著高于对照组(60.0%),差异具有统计学意义(P<0.05).实验组患者的血管内皮生长因子C水平显著低于对照组,差异具有统计学意义(P<0.05).结论 非小细胞肺癌多发脑转移患者应用厄洛替尼联合全脑放射临床治疗效果较好,能够在很大程度上提高生存率,改善内皮生长因子C水平.
Non small cell lung cancer patients with multiple brain metastases with erlotinib combined with whole brain radiation therapy clinical observation and effect of C on vascular endothelial growth factor level
Objective To study the analysis of non-small cell lung cancer patients with multiple brain metastases with erlotinib combined with whole brain radiation therapy clinical observation and effect of C on vascular endothelial growth factor level. Methods 40 cases of non - small cell lung cancer patients with multiple brain metastases treated in Taizhou tumor hospital from January 2015 to April 2016 were selected and randomly divided into the control group and the experimental group, with 20 patients in each group. The control group and the experimental group patients were given clinical treatment of whole brain radiotherapy, the control group was given routine treatment, the experimental group received erlotinib. The clinical effects of the 2 groups were compared and analyzed. Results After the corresponding treatment, the experimental group of 20 patients, 8 cases of complete remission, 7 cases of partial remission, the number of effective treatment for 15 cases, the treatment rate was 75.0%. Of the patients in the control group, 6patients had complete remission, and 4 patients had partial remission. The effective rate was 50%. Available, the effective rate of the treatment group (75.0%) was significantly higher than that of the control group (50.0%), with statistical difference (P<0.05). The survival rate of the experimental group after one year (80.0%) was significantly higher than that of the control group (60.0%), with statistical difference (P<0.05). The level of vascular endothelial growth factor (C) in the experimental group was significantly lower than that in the control group (P<0.05). Conclusion Non small cell lung cancer patients with multiple brain metastases with erlotinib combined with radiotherapy in the clinical treatment effect of whole brain is better, can improve the survival rate in a large extent, improve the endothelial growth factor C levels, with the further promotion of the clinical significance.

non small cell lung cancer patients with multiple brain metastasesclinical treatment of whole brain radiationerlotinibvascular endothelial growth factor C

刘丽丹、叶瑞智、文强

展开 >

浙江省台州市肿瘤医院 肿瘤放疗科,浙江 台州 317502

非小细胞肺癌多发脑转移 全脑放射临床治疗 厄洛替尼 血管内皮生长因子C

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(9)
  • 3
  • 8